These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 21223817

  • 1. [Impact of neoadjuvant hormonal therapy on the permanent ¹²⁵I-seed brachytherapy for localized high-risk prostate cancer].
    Zhuang HY, Xu XM, Peng T, Lin CP.
    Zhonghua Yi Xue Za Zhi; 2010 Dec 28; 90(48):3418-20. PubMed ID: 21223817
    [Abstract] [Full Text] [Related]

  • 2. [Application of neoadjuvant hormonal therapy in (125)I permanent seed implantation for prostate cancer].
    Cui X, Li Q, Xu JJ, Li J, Ou TW.
    Zhonghua Yi Xue Za Zhi; 2012 Oct 16; 92(38):2710-2. PubMed ID: 23290112
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):16-22. PubMed ID: 19289266
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
    Petit JH, Gluck C, Kiger WS, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I.
    Urol Oncol; 2008 Sep 01; 26(4):372-7. PubMed ID: 18367113
    [Abstract] [Full Text] [Related]

  • 7. [Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].
    Guinot JL, Ricós JV, Gimeno J, Tortajada MI, Carrascosa M, Santos M, Casanova J, Soler P, Crispín V, Arribas L.
    Actas Urol Esp; 2011 Jun 01; 35(6):339-44. PubMed ID: 21481974
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
    Evers J, Kupper N, Kessing D, Davits R, Engelen A, Poortmans P, Mols F.
    Urology; 2010 Nov 01; 76(5):1150-6. PubMed ID: 20869105
    [Abstract] [Full Text] [Related]

  • 11. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS.
    J Urol; 2004 Mar 01; 171(3):1098-104. PubMed ID: 14767279
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
    Prada PJ, Juan G, González-Suárez H, Fernández J, Jimenez I, Amón J, Cepeda M.
    BJU Int; 2010 Jul 01; 106(1):32-6. PubMed ID: 20067460
    [Abstract] [Full Text] [Related]

  • 14. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
    Ishiyama H, Satoh T, Kitano M, Tsumura H, Kotani S, Okusa H, Uemae M, Baba S, Hayakawa K.
    Jpn J Clin Oncol; 2008 Jul 01; 38(7):469-73. PubMed ID: 18577509
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Hormonal Therapy Improves the Outcomes of Patients Undergoing Radioactive Seed Implantation for Localized Prostate Cancer.
    Stone NN, Stock RG.
    Mol Urol; 1999 Jul 01; 3(3):239-244. PubMed ID: 10851329
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1367-82. PubMed ID: 15275722
    [Abstract] [Full Text] [Related]

  • 18. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer.
    Okaneya T, Nishizawa S, Nakayama T, Kamigaito T, Hashida I, Hosaka N.
    Int J Urol; 2007 Jul 01; 14(7):602-6. PubMed ID: 17645602
    [Abstract] [Full Text] [Related]

  • 19. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar 01; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 20. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    Joseph J, Al-Qaisieh B, Ash D, Bottomley D, Carey B.
    BJU Int; 2004 Dec 01; 94(9):1235-8. PubMed ID: 15610096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.